Jon Pilcher sat down with Stephen Mayne from Intelligent Investor to talk through where things stand for Neuren - from the EU regulatory turnaround for DAYBU® to how the company is funding the next chapter of its pipeline.

Neuren Pharmaceuticals: The Next Chapter - Intelligent Investor

Note: This content is hosted on Intelligent Investor and access is subject to their platform policies.